The experimental and theoretical results obtained in this study shed light on the anticancer activity and its underlying mechanisms of butoxy MG against human NSCLC cell lines expressing wild-type EGFR and mutant EGFR, which might be useful to develop this compound as a novel anticancer agent and/or can be used as a theoretical guidance for designing and developing a new compound targeting STAT3 and Akt signaling pathways. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.